It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
Total compensation is similar to the industry average C4 Therapeutics' three-year loss to shareholders was 87% while its EPS was down 2.9% over the past three years Shareholders will probably not be too impressed with the underwhelming results at C4 Therapeutics, Inc. NASDAQ:CCCC ) recently. At the upcoming AGM on 20th of June, shareholders can hear from the board including their plans for turning around performance. This will be also be a chance where they can challenge the board on company direction and vote on resolutions such as executive remuneration. We present the case why we think CEO compensation is out of sync with company performance. View our latest analysis for C4 Therapeutics Comparing C4 Therapeutics, Inc.'s CEO Compensation With The Industry According to our data, C4 Therapeutics, Inc. has a market capitalization of US$331m, and paid its CEO total annual compensation worth US$3.8m over the year to December 2023. We note that's an increase of 46% above last y
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of DirectorsGlobeNewswire
- We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $8.00. They now have an "equal weight" rating on the stock.MarketBeat
- C4 Therapeutics, Inc. (NASDAQ: CCCC) had its price target raised by analysts at Stifel Nicolaus from $13.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
CCCC
Earnings
- 5/8/24 - In-Line
CCCC
Sec Filings
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- 6/21/24 - Form 4
- CCCC's page on the SEC website